Anaemia: Clinical Trials

10 completed, 3 terminated, 1 unknown. 14 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	14	Completed 10, Terminated 3, Unknown 1
Phase 3	1	Completed 1

Follow Anaemia: new trials by email Literature Review of Anaemia trials Research Report on Anaemia

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe) Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe) - Anaemia	Phase 2	Completed	GlaxoSmithKline	15	2019-07-30	2024-03-27
Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF) Daprodustat, Darbepoetin alfa, Acetylcholine - Anaemia	Phase 2	Terminated	GlaxoSmithKline	6	2019-01-10	2024-03-27
Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) Daprodustat, Epoetin alfa - Anaemia	Phase 2	Completed	GlaxoSmithKline	105	2017-07-27	2021-06-03
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent GSK1278863, GSK1278863 matching Placebo - Anaemia	Phase 2	Completed	GlaxoSmithKline	103	2016-02-17	2020-02-25
Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia GSK1278863, Placebo - Anemia, Anaemia	Phase 2	Terminated	GlaxoSmithKline	15	2014-06-11	2026-08-04
Safe and Efficacious Iron for Children in Kenya Low-dose iron as NaFeEDTA, Conventional dose iron as ferrous salt, Placebo - Anaemia	Phase 2 / Phase 3	Completed	London School of Hygiene and Tropical Medicine	338	2014-06-01	2015-04-10
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease GSK1278863, Placebo - Anaemia	Phase 2	Completed	GlaxoSmithKline	97	2013-11-05	2018-02-12
Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia GSK1278863, Placebo, rhEPO - Anaemia	Phase 2	Completed	GlaxoSmithKline	216	2013-11-01	2018-06-08
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD) GSK1278863, rhEPO - Anaemia	Phase 2	Completed	GlaxoSmithKline	252	2013-10-31	2018-10-12
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease GSK1278863, rhEPO - Anaemia	Phase 2	Completed	GlaxoSmithKline	80	2012-05-23	2017-11-14
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis GSK1278863, Placebo - Anaemia	Phase 2	Completed	GlaxoSmithKline	72	2012-05-17	2017-11-09
Impact of Vitamin B12 Supplementation With Iron and Folic Acid on Adolescent Girls Iron, Folic acid and Cyanocobalamin, Iron and Folic Acid - Anaemia	Phase 2	Unknown	Indian Council of Medical Research	360	2012-01-01	2012-02-28
Optimal Transfusion in Anaemic Cancer Patients Treated With Chemotherapy (HaemOPtimal) Blood transfusion - Cancer, Anaemia	Phase 2	Terminated	Copenhagen University Hospital, Rigshospitalet	180	2010-03-01	2014-11-05
Iron-fortified Whole Maize Flour Trial NaFeEDTA, Electrolytic Iron - Anaemia	Phase 2	Completed	Wageningen University	412	2004-05-01	2010-04-21

Narrower conditions

Anemia (14)  ·  Renal Insufficiency, Chronic (8)  ·  Neoplasms (1)  ·  Renal Insufficiency (1)

Broader conditions

Hematologic Diseases (14)  ·  Hemic and Lymphatic Diseases (14)  ·  Chronic Disease (8)  ·  Disease Attributes (8)  ·  Female Urogenital Diseases (8)  ·  Female Urogenital Diseases and Pregnancy Complications (8)  ·  Kidney Diseases (8)  ·  Male Urogenital Diseases (8)  ·  Pathologic Processes (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Urogenital Diseases (8)  ·  Urologic Diseases (8)  ·  Renal Insufficiency (7)

Interventions

GSK1278863 (10)  ·  Fe(III)-EDTA (2)  ·  Iron (2)  ·  Acetylcholine (1)  ·  Blood Transfusion (1)  ·  Darbepoetin alfa (1)  ·  Epoetin Alfa (1)  ·  Folic Acid (1)  ·  Nitroprusside (1)  ·  Vitamin B 12 (1)  ·  omega-N-Methylarginine (1)

Sponsors

GlaxoSmithKline (10)  ·  Copenhagen University Hospital, Rigshospitalet (1)  ·  Indian Council of Medical Research (1)  ·  London School of Hygiene and Tropical Medicine (1)  ·  Wageningen University (1)

Countries

United States (8)  ·  Canada (5)  ·  Germany (5)  ·  Denmark (4)  ·  Japan (3)  ·  Russia (3)  ·  Spain (3)  ·  Sweden (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Czechia (2)  ·  France (2)  ·  Hungary (2)  ·  Norway (2)  ·  Poland (2)

Top investigators

Hans Verhoef, PhD (2)  ·  David L Mwaniki, PhD (1)  ·  Dr. Anupa Siddhu, Ph.D (1)  ·  Dr. Gurdayal S Toteja, Ph.D (1)  ·  Dr. Naval K Vikram, M.D. (1)  ·  Dr. Neena Bhatia, Ph.D (1)  ·  Frans J Kok, PhD (1)  ·  Morten Sorensen, MD, Phd (1)  ·  Pauline EA Andang'o, MND (1)  ·  Priyanka Gupta, M.Sc (1)  ·  Saskia JM Osendarp, PhD (1)

Results publications

PMID 36005278, PMID 26494831, PMID 17531887, PMID 28449690, PMID 28770094, PMID 29391008, PMID 34932836, PMID 41114449

NIH funding

2015 (1), 2017 (1)